
|Videos|October 18, 2013
Ipilimumab in the Adjuvant Setting for Melanoma
Author(s)Vernon K. Sondak, MD
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
Advertisement
Clinical Pearls
Vernon K. Sondak, MD, chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, discusses the use of ipilimumab in the adjuvant setting for patients with melanoma.
- There are a number of studies looking at ipilimumab in the adjuvant setting
- There has been a fair amount of toxicity associated with the 10-mg/kg dosage
- Adjuvant therapy with ipilimumab outside of a clinical trial is not recommended
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCENT-07: Sacituzumab PFS Not Significant vs Chemo in HR+/HER2- BC
2
Aromatase Inhibitors Favored as Adjuvant ET in HR+/HER2+ Early Breast Cancer
3
T-DXd Plus Pertuzumab Yields Favorable Benefit Over SOC in HER2+ Breast Cancer
4
Giredestrant Improves IDFS vs SOC in ER+/HER2– Early Breast Cancer
5










































